Miragen Therapeutics Inc

+0.01 (+1.31%)
Products, Regulatory

MiRagen Announces Internal Review Of Prelim Topline Data For Phase 2 Solar Clinical Trial Of Cobomarsen

Published: 10/05/2020 20:30 GMT
Miragen Therapeutics Inc (MGEN) - Miragen Announces Internal Review of Preliminary Topline Data for the Phase 2 Solar Clinical Trial of Cobomarsen in Patients With Cutaneous T-cell Lymphoma (ctcl).
Miragen - Preliminary Data in 37 Patients Suggest That Cobomarsen Lacks a Compelling Result for Study's Primary Endpoint.
Miragen Therapeutics Inc - Continues to Evaluate Strategic Alternatives for Company.
Miragen Therapeutics Inc - Downsized Solar Study is Not Statistically Powered for Superiority Or Equivalence.
Miragen Therapeutics Inc - Progression Free Survival (pfs), a Secondary Endpoint for Study, Indicates a Treatment Effect in Favor of Cobomarsen.
Miragen Therapeutics Inc - Cobomarsen Was Well Tolerated, With No Patient Discontinuations Due to Cobomarsen-related Adverse Events.